/PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) CEO and President, Richard Garr, will present at the World Stem Cells & Regenerative Medicine Congress, on Thursday, May 22, at 11:35 a.m. BST in London, UK (http://www.terrapinn.com/conference/stem-cells/index.stm). Neuralstem is currently in a Phase II clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) with its NSI-566 stem cells and has been approved to commence a Phase I study in spinal cord injury with the same cells. The company has also completed a Phase Ib trial testing its first-in-class neurogenic compound, NSI-189, in patients with major depressive disorder (MDD).
GERMANTOWN, Md., May 16, 2014Mr. Garr's talk is called "Sustainable Growth of Regenerative Medicine: Ensuring Long Term Development and Patient Access to Transformative Cell Therapies." He will also give an update on the clinical programs, including results from the NSI-189 Ib trial.
Neuralstem's patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem's NSI-566 spinal cord-derived stem cell therapy is in Phase II clinical trials for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The company has received FDA approval to commence a Phase I safety trial in chronic spinal cord injury.
Neuralstem also maintains the ability to generate stable human neural stem cell lines suitable for systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate neurons, possibly reversing pathologies associated with certain central nervous system conditions. The company has completed a Phase I safety trial evaluating NSI-189, its first neurogenic small molecule product candidate, for the treatment of major depressive disorder (MDD). Additional indications might include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).
For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn.
Cautionary Statement Regarding Forward Looking Information:
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2013 and Form 10-Q for the period ended March 31, 2014.
Logo - http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO
SOURCE Neuralstem, Inc.